<DOC>
	<DOCNO>NCT01022476</DOCNO>
	<brief_summary>This phase I/II , multi-center study design determine pharmacokinetic profile Raltegravir patient end stage liver disease assess drug-drug interaction Raltegravir combine immunosuppressive therapy liver transplant recipient .</brief_summary>
	<brief_title>Raltegravir Patients With End Stage Liver Disease Transplant Recipients</brief_title>
	<detailed_description>HIV infect patient stable plasma HIV-RNA 50 copy per mL severe liver dysfunction switch antiretroviral regimen combination raltegravir ( one 400 mg pill twice daily ) two fully active molecule among nucleosi ( ti ) de analog enfuvirtide first period least 3 month second period least 3 month liver transplantation , need , steady state anticalcineurin reach . Pharmacokinetic parameter raltegravir calculate severe liver dysfunction period liver transplantation . Pharmacokinetic parameter cyclosporine ( tacrolimus contra indication cyclosporine ) compare administrated alone combine raltegravir . Patients follow accord standard care . This study divide two distinct period ( 1 2 ) last 3 month . Period 1 start inclusion study generally include switch raltegravir . Period 2 start liver transplantation .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Age ≥ 18 Documented HIV1 infection , hepatitis B C coinfection allow Plasma viral load screen visit 50 copy per mL least 6 month Patient severe liver failure ( Meld Score ≥ 15 and/or refractory ascites and/or haemorrhage digestive tract and/or hepatic encephalopathy ) take part period 1 Patient eligible liver transplant wait list immediate post transplantation take part period 2 Abstinence alcohol intake least 6 month ( WHO norm ) Withdrawal intravenous drug use least 6 month ( methadone substitution permit ) No ongoing class C opportunistic infection ( 1993 CDC classification ) Patient whose clinical immunovirological condition allow triple therapy raltegravir + 2 NRTI raltegravir + NRTI + enfuvirtide Patient whose HIV population , accord cumulative genotype carry viral RNA together treatment history ( available interpret per ANRSAC11 algorithm version no.19 ) present profile mutation associate resistance raltegravir sensitive least two fully active* agent select among nucleoside/nucleotide reverse transcriptase analog NRTI ( abacavir , lamivudine , emtricitabine , tenofovir ) enfuvirtide *An ARV agent consider fully active cumulative genotype show mutation associate resistance mutation associate `` possible resistance '' Patient experience viral escape treatment combine 3TC , FTC raltegravir Patient register cover social security scheme For woman childbearing potential , use barrier contraceptive method sexual intercourse negative pregnancy test ( plasma ßHCG ) screen visit Informed consent form sign screen visit late More two virological failure antiretroviral treatment Currently receive treatment agent development ( apart authorization temporary use ) Plasma viral load screen visit ≥ 50 copy per mL least last 6 month Pregnant woman , woman liable become pregnant , breastfeed woman , contraception , refusal use contraception All condition ( include limit alcohol intake drug use ) liable compromise , investigator 's opinion , safety treatment and/or patient 's compliance protocol Patient effective option NRTI +/ enfuvirtide ( define inclusion criterion ) Ongoing treatment interferonalpha ribavirin hepatitis C Concomitant medication include one agent liable induce UGT1A1 reduce raltegravir concentration : antiinfective agent : rifampicin/rifampin psychotropic/antiepileptic agent : phenytoin , phenobarbital , carbamazepine steroidal antiinflammatory drug : dexamethasone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Immunosuppressive Agents</keyword>
	<keyword>Severe hepatic insufficiency</keyword>
	<keyword>Liver Transplantation</keyword>
	<keyword>Additional Keywords</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>Hepatocarcinoma</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>